Information on Coronavirus (COVID-19)

Your health and well-being is our highest priority. As we welcome you back to services, please continue to stay informed with Doylestown Health's response to COVID-19. Learn more

Welcome Back: A message from Doylestown Health's President and CEO, Jim Brexler

We've established several new precautions to protect the health of our patients and staff. Hear from our President and CEO, Jim Brexler, and learn about the additional steps we've taken to keep you safe. Learn more

Clinical Trials and Research Programs

Cancer Clinical Trials and Research Programs

Doylestown Health's Cancer Institute is a member of the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in the United States, and conducts clinical trials in all types of adult cancers. ECOG is funded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).

Doylestown Health conducts research and clinical trials in collaboration with Thomas Jefferson's Sidney Kimmel Cancer Network. Our cancer care team is proud to offer local patients the most current opportunities and the convenience of participating in these vitally important cancer research programs close to home.


Peggy Hughes, RN, BSN, OCN
Clinical Trial Nurse Coordinator

Doylestown Health is currently enrolling patients in the following approved oncology protocols:

Breast Cancer


  • Phase III Randomized Trial
  • Breast Cancer Weight Loss Study (BWEL Study)
  • Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Stage Breast Cancer


  • A randomized phase III trial of adjuvant chemotherapy comparing doxorubicin plus cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node negative, triple negative invasive breast cancer.


  • Phase III Randomized Trial
  • Evaluates the effect of aspirin vs placebo on the rate of breast cancer recurrence


  • A randomized non-inferiority trial comparing patients monitored with Serum Tumor Markers versus usual care in patients with metastatic, hormone receptor positive breast cancer.


  • A randomized, phase III trial to evaluate the efficacy and safety of Pembrolizumab as adjuvant therapy for triple negative breast cancer with residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy.

Bladder (Urothelial) Cancer


  • Phase III Randomized Trial
  • Evaluates disease free survival and overall survival in patients with muscle-invasive urothelial cancer treated with adjuvant Pembrolizumab vs. observation.

Metastatic Cancer


  • Molecular Analysis for Therapy Choice
  • Non-randomized phase II "basket" trial
  • Requires biopsy of tumor


Cancer Genetics and Risk Registry

  • To learn more about inherited cancer risk, familial cancers, and genetic mutations predisposing to cancer
  • Open to adults who have been diagnosed with any type of cancer
  • Open to adults with a family history of cancer

Rare Tumors

S1609 DART

  • Dual Anti-CTLA4 and Anti-PD-1 Blockade in rare tumors (Combination Opdivo plus Yervoy).

Prostate Cancer


  • A non-therapeutic international registry to describe the practice patterns of therapeutic agents for advance prostate cancer, to identify associations between treatment sequences or combinations and overall survival, to define the patient experience and identify unmet needs in their treatment, and to identify clinical and molecular disease subtypes that predict response to individual treatments, combinations or sequences.

For more information about Doylestown Health's open cancer trials visit the U.S. National Institutes of Health's Clinical Trials database.

Learn more about clinical trials

Blog Posts

Coronavirus (COVID-19) Update from Doylestown Health
Information on Coronavirus (COVID-19)

(Updated 10/21/20) Doylestown Health is coordinating with federal, state and local agencies to prevent the spread of potential COVID-19 (Coronavirus).

View All Articles

Upcoming Classes and Events

For more information